Tatva Chintan Pharma Chem LtdNSE:TATVA
Current view Q1 2027
World's second-biggest maker of the chemicals behind vehicle exhaust catalysts, and tighter Euro-7 rules are now turning into real orders across all four products. A new plant is approved because the existing one is nearly full. Management has a long habit of missing its own timelines, and the stock is very expensive.
Latest exchange filings last 5 · 5 after Q1 2027
- 17 Sep ’26Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015. ↗
- 8 Sep ’26Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015. ↗
- 8 Sep ’26CRISIL upgraded Tatva Chintan’s bank facilities rating to A-/Stable and A2+ for Rs245 crore facilities. ↗
- 28 Aug ’26Newspaper Advertisement - Disclosure under Regulation 30, 44 and 47 of the SEBI (LODR) Regulations, 2015, as .... ↗
- 27 Aug ’26Book closure 12-25 Sep 2026; record date 11 Sep for final dividend and 30th AGM voting. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q1 2027
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q1 2027
| Metric | This year vs lastYoY · vs Q1 2026 | vs the quarter beforeQoQ, sequential · vs Q4 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +42.7% | +24.6% | +6.1% | +11.0% |
| Operating profit | ▲ +88.2% | +14.3% | +15.5% | +6.1% |
| EPS | ▲ +140.5% | +54.9% | −4.3% | −7.1% |
| PAT | ▲ +128.6% | +60.0% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +42.7%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Weak36/100
Earnings are shrinking, not growing. Profit per share fell 4% a year over the window measured. Nothing compounds from here until that turns, whatever the price does.
No forward view — earnings are not compounding, so there is nothing to project.
Multiple moved without the earnings — the return sits in sentiment.
How this is calculated
Band capped: earnings are not growing over the measured window.
Growth rate used: -4.3% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Speciality Chemicals · 6 of 94 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Tatva Chintan | ₹1,754 | 78.3× | ₹4,102 Cr | 7.2% | +155.3% | +43.0% |
| Pidilite Inds. | ₹1,596 | 61.4× | ₹1.62 L Cr | 31.0% | +28.2% | +21.3% |
| Gujarat Fluoroch | ₹4,586 | 81.6× | ₹50,373 Cr | 9.6% | +21.4% | +24.0% |
| Navin Fluo.Intl. | ₹8,415 | 54.4× | ₹43,180 Cr | 21.0% | +107.7% | +44.1% |
| Deepak Nitrite | ₹1,605 | 27.6× | ₹21,891 Cr | 11.4% | +207.5% | +36.4% |
| Aether Industri. | ₹1,639 | 90.7× | ₹21,754 Cr | 11.9% | +28.0% | +27.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | broadly flat | operating margin 19% → 19% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it arrived as cash | 42% last year, 95% over three · free cash flow −₹82 cr, positive in 0 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹120 cr — 0.15× its own equity (was 0.05×) |
| Is it being collected? | collection is steady | 86 days to collect, up 1 in a year · cash cycle 310 days |
| Who has been buying? | the promoters have held steady | promoters 72.0%, 72.0% → 72.0% over 2.8 years · FIIs 3.9% (+0.7) · DIIs 3.1% (−2.0) · shareholders 74,628 → 64,921 |
| What does it earn on its capital? | earns little on its capital | ROCE 7.2% · ROE 5.5% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 22.5%
- Company's working capital requirements have reduced from 133 days to 92.0 days
Against it
- Stock is trading at 5.12 times its book value
- The company has delivered a poor sales growth of 11.0% over past five years.
- Company has a low return on equity of 3.68% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.15%
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.